Sir, Carbapenemase-producing Enterobacteriaceae are still rare in Scandinavia and the majority of reported cases have been clearly linked to hospitalization abroad.
1 -4 New Delhi metallo-blactamase-1 (NDM-1) was first identified in 2008 in Klebsiella pneumoniae and Escherichia coli isolates from a Swedish patient following hospitalization in India. 5 In 2009 the HPA in the UK issued an addendum to National Resistance Alert 3 (http://www. hpa.org.uk/web/HPAwebFile/HPAweb_C/1248854045473) due to a worrying increase in NDM-1-producing clinical strains of Enterobacteriaceae. Many of the UK cases could be linked to recent medical exposure in India or Pakistan. 6 Recent epidemiological studies describe the prevalence of NDM-1-producing Enterobacteriaceae in India and warn of the potential for worldwide spread.
6,7 NDM-1-producing Enterobacteriaceae have recently been reported from the USA, 7 the Netherlands, 8 Australia 6,9 and Canada. 10 Here we report two cases of NDM-1-producing Enterobacteriaceae identified in Norway. Case 1 was an elderly male from India who required hospitalization for urosepsis on two occasions during a visit to Norway. The patient had undergone a transurethral resection of the prostate in India in early 2009. The postoperative period was complicated by partial urinary incontinence and recurrent urinary tract infections. The patient had been treated with several courses of antibiotics, including faropenem, a penem available for oral administration in India. Two weeks after arrival in Norway in late 2009 (5 months post-operative) the patient was admitted to hospital for urosepsis. A CTX-M-producing Klebsiella pneumoniae was isolated from urine and blood cultures. The isolate was resistant to ertapenem, intermediate to meropenem and susceptible to imipenem using Etest (bioMérieux) and EUCAST clinical breakpoints, but no carbapenemase activity was detected by biochemical and molecular assays. The infection was cleared after initial treatment with meropenem followed by colistin in combination with rifampicin and urinary catheter insertion. Subsequent urological investigation revealed metastatic cancer of the prostate. The patient remained in Norway, but 3 months later, in early 2010, was re-admitted due to urinary retention and urosepsis. An NDM-1-producing Escherichia coli (K71-77) was isolated from urine and blood cultures. Antimicrobial susceptibility testing showed that the E. coli isolate was resistant to penicillins and cephalosporins and intermediate to aztreonam (Table 1) . No synergy was observed with b-lactamase inhibitors. The isolate was resistant to ertapenem, but susceptible to both meropenem and imipenem. In addition, the isolate showed high-level resistance to aminoglycosides and ciprofloxacin, but was susceptible to tigecycline, colistin and trimethoprim/sulfamethoxazole. Carbapenemase activity was detected in bacterial cell extracts, which was inhibited by EDTA. PCR and DNA sequence analysis revealed bla NDM-1 (primers used for detection of resistance genes are listed in Table S1 , available as Supplementary data at JAC Online). The isolate harboured the plasmid-mediated AmpC gene bla CMY-6 , but was negative for extended-spectrum b-lactamase (ESBL) genes (bla TEM , bla SHV and bla CTX-M ) and 16S rRNA methylases. Multilocus sequence typing (MLST) 11 revealed sequence type (ST) 410, which belongs to ST complex 23. The infection was cleared after initial treatment with meropenem followed by trimethoprim/sulfamethoxazole.
Case 2 was a Norwegian female patient who was hospitalized in India in 2010 following a traffic accident. The patient underwent orthopaedic surgery and prophylactic antibiotic treatment (linezolid) in India prior to her repatriation. On arrival in Norway the patient was admitted directly to hospital. A multidrugresistant K. pneumoniae (K66-45) isolate was cultured from a catheter urine sample. The catheter had been inserted in India. The urine isolate was judged on clinical grounds to represent catheter colonization and did not require antibiotic treatment. The isolate was resistant to penicillins, cephalosporins and aztreonam (Table 1) . Synergy was observed with ceftazidime and clavulanic acid using combination discs. The isolate expressed resistance to meropenem and ertapenem and intermediate resistance to imipenem. Moreover, the isolate showed high-level resistance to aminoglycosides, ciprofloxacin and trimethoprim/sulfamethoxazole, and resistance to tigecycline. The isolate was susceptible to colistin only. Carbapenemase # The Author 2010. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com activity was detected in bacterial cell extracts, which was inhibited by EDTA. PCR and sequence analysis revealed bla NDM-1 . In addition, bla TEM-1 , bla SHV-11 , bla CTX-M-15 and the 16S rRNA methylase gene armA were detected. MLST analysis 12 showed ST11, a single-locus variant of ST258, which is associated with the global dissemination of K. pneumoniae carbapenemase (KPC) -producing K. pneumoniae, suggesting a potential for further spread and dissemination. 13 To the best of our knowledge this is the first description of bla NDM-1 -producing Enterobacteriaceae isolates in Norway and contributes to current knowledge of the global dissemination of this carbapenemase resistance gene. The relatively long time period between hospitalization in India and the identification of the NDM-1 isolate in Case 1 (8 months) suggests faecal colonization over long time periods.
The NDM-1 enzyme is capable of inactivating virtually all b-lactam antibiotics and is often associated with other resistance mechanisms, resulting in extremely drug-resistant Gramnegative bacteria. 6 Of concern is the fact that the NDM-1 gene is located on transferable plasmids, and dissemination into multiple genera-including K. pneumoniae, E. coli, Enterobacter spp., Citrobacter freundii, Morganella morganii, Proteus spp., Providencia spp. and Acinetobacter baumannii-has already occurred. 6, 14 Microbiological laboratories must maintain a high level of alertness during the interpretation of antibiograms. The detection of NDM-1-producing Enterobacteriaceae cannot be based solely on the current clinical breakpoints for carbapenems. This is also the case for strains expressing other carbapenemases.
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The relatively low carbapenem MIC values observed for isolate K71-77 highlights this problem.
The global dissemination of carbapenemase-producing Gramnegative bacteria has to be controlled. Of importance is the prudent use of antibiotics, good and rapid microbiological laboratory services and targeted infection control measures. The epidemiological situation should be carefully monitored by including the characterization of clinical strains of Enterobacteriaceae with reduced susceptibilities to carbapenems in surveillance systems. Further, patients who have been hospitalized in countries with a high prevalence of carbapenemase-producing Enterobacteriaceae should be screened upon hospital admission. 
